More evidence of consolidation in the digital health category has come with the news that Aptar has bought Singapore’s Healint, which develops patient support apps as well
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh